NEUTRALIZING MONOCLONAL ANTIBODIES TO RESPIRATORY SYNCYTIAL VIRUS

The present invention relates to the identification and cloning of a novel neutralizing human monoclonal antibody to the Respiratoy Syncytial Virus. The invention provides such antibodies, fragments of such antibodies retaining RSV-binding ability, chimeric antibodies retaining RSV-binding ability,...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	CROWE, JAMES, E., JR, PILKINGTON, GLENN, R, GILMOUR, PAGE, S, CHANOCK, ROBERT, M, MURPHY, BRIAN, R
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES MEASURING MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PHYSICS PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPIRITS TESTING VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present invention relates to the identification and cloning of a novel neutralizing human monoclonal antibody to the Respiratoy Syncytial Virus. The invention provides such antibodies, fragments of such antibodies retaining RSV-binding ability, chimeric antibodies retaining RSV-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Finally, the invention provides for diagnostic and therapeutic methods employing the antibodies and nucleic acids of the invention. La présente invention concerne l'identification et le clonage d'un nouvel anticorps monoclonal neutralisant, d'origine humaine, et dirigé contre le Virus Syncytial Respiratoire (RSV). L'invention concerne de tels anticorps, des fragments de tels anticorps restant capables de liaison avec le RSV, des anticorps chimériques restant capables de liaison avec le RSV, et des compositions pharmaceutiques comportant de tels anticorps. L'invention concerne en outre, non seulement des acides nucléiques isolés codant les anticorps de l'invention, mais aussi des cellules hôtes transformées au moyen de ces acides nucléiques. L'invention concerne enfin des procédés de diagnostic et de traitement utilisant les anticorps et les acides nucléiques de l'invention.